Condition: Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung Cancer · Sponsor: Novartis Pharmaceuticals
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University of California LA | Los Angeles, California, United States | Recruiting |
| Florida Cancer Specialists | Fort Myers, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| WA Uni School Of Med | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center Uni of Te | Houston, Texas, United States | Recruiting |
| Fred Hutch Cancer Research | Seattle, Washington, United States | Recruiting |
| Novartis Investigative Site | Clayton, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Melbourne, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Toronto, Ontario, Canada | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726148